“Today marks an important milestone in our fight against the pandemic."

AstraZeneca’s CEO as the company becomes the third pharmaceutical company in recent weeks to announce promising clinical trial results for a COVID-19 vaccine.

  • THE LATEST: AstraZeneca’s CEO says the “vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency. Furthermore, the vaccine’s simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval.”
    • Last week, Moderna announced the results of its Phase 3 COVID-19 vaccine trial show it’s nearly 95% effective.
      • Also last week, the U.S. gov’t granted emergency use authorization for a first of its kind at-home COVID-19 test that provides results in 30 min. or less. So far, it’s catching 94% of all positive cases, and 98% of all negative cases.
    • Two weeks ago, Pfizer announced the results of its Phase 3 COVID-19 vaccine trial show it’s over 90% effective. Pfizer became the first to apply for emergency use authorization from the FDA last week.
  • ABOUT THE ASTRAZENECA TRIALS: The trials involve over 23,000 participants in the UK and Brazil. The vaccine was developed by the University of Oxford and AstraZeneca using a weakened version of the common cold virus.
    • AstraZeneca says its vaccine is at least 62% effective (when given as a half dose followed by a full dose one month later) and up to 90% effective (when given as two full doses one month apart).
  • FYI: Unlike the other vaccines, the AstraZeneca vaccine does not need to be stored at ultra-cool temperatures, and it’s expected to be less expensive than those from Pfizer and Moderna.
  • BIG PICTURE: Health and Human Services Secretary Alex Azar said last week that he expects the U.S. will have 40 million doses of vaccines available for high-risk and vulnerable populations, such as frontline workers, by the end of the year.